Deal Announcements

Hydra Biosciences Raises Third Venture Capital Round

Friday, March 14, 2008 5:36:00 AM PDT | VentureDeal Staff

CAMBRIDGE, MA -- Pharmaceuticals company Hydra Biosciences, Inc. has closed its series C round of venture capital financing, receiving $34 million in total, according to a report in PE Hub.

Hydra is developing "molecular regeneration engines", new cardiovascular therapies and drugs that it says are targeting new ion channels.

Advanced Technology Ventures led the syndicate, which included previous investors Abingworth Management Inc., Bioventures Investors, Lilly Ventures, New Enterprise Associates and Polaris Venture Partners.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin

PCI - Level1